Henry Gosebruch is Chief Executive Officer and a member of the Executive Committee and of the Board of Directors at Lakefront Biotherapeutics. He joined the company in May 2025. Prior to joining Lakefront, he was President and CEO of Neumora Therapeutics (NASDAQ: NMRA), advancing neuroscience-focused clinical programs. Before that, he served as Executive Vice President and Chief Strategy Officer at AbbVie, overseeing corporate strategy, M&A, alliance management, and business development. Earlier, he spent more than 20 years at J.P. Morgan, serving as Co-Head of North American M&A. He serves on the Board of Emalex Biosciences, and on the Advisory Board of the University of Pennsylvania Life Sciences & Management Program. He holds a BA from the Wharton School at the University of Pennsylvania.
